Skip to main content
SpringerLink
Log in

Landscape of Immunotherapy in Genitourinary Malignancies

  • Chapter
  • First Online:
Immunotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1342))

Abstract

The past decade has witnessed a revolution in the development of immune checkpoint inhibitors for the treatment of multiple tumor types, including genitourinary cancers. Immune checkpoint inhibitors have notably improved the treatment outcomes of patients with metastatic renal cell carcinoma and metastatic urothelial carcinoma. In prostate cancer, the role of immunotherapy with checkpoint inhibitors is not yet established except for microsatellite instability high (MSI-H) tumors. Other immunotherapeutic approaches that have been explored in these malignancies include cytokines, vaccines, and cellular therapy. Ongoing studies are exploring the use of immunotherapy combinations as well as combination with chemotherapy and targeted therapy in these types of tumors. The use of immunotherapy beyond the metastatic setting is an active area of research. Moreover, there is great interest in biomarker development to predict response to immunotherapy and risk of toxicity. This book chapter is a comprehensive review of immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA: A Cancer Journal for Clinicians, 65(1), 5–29.

    Google Scholar 

  2. Fisher, R., Gore, M., Larkin, J. (Eds.). (2013). Current and future systemic treatments for renal cell carcinoma. Seminars in Cancer Biology, 23(1), 38–45. Elsevier.

    Google Scholar 

  3. Howlader, N., Noone, A., Krapcho, M., Miller, D., Bishop, K., Kosary, C., et al. (2017). SEER cancer statistics review, 1975–2014. National Cancer Institute;2018.

    Google Scholar 

  4. Heng, D. Y., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., et al. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. Journal of Clinical Oncology, 27(34), 5794–5799.

    Article  CAS  PubMed  Google Scholar 

  5. Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 17(8), 2530–2540.

    Article  CAS  PubMed  Google Scholar 

  6. Vachhani, P., & George, S. (2016). VEGF inhibitors in renal cell carcinoma. Clinical Advances in Hematology & Oncology, 14(12), 1016–1028.

    Google Scholar 

  7. Buti, S., Leonetti, A., Dallatomasina, A., & Bersanelli, M. (2016). Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy. Core Evidence, 11, 23–36.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., et al. (2018). Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine, 378(14), 1277–1290.

    Article  CAS  Google Scholar 

  9. Walsh, N., Larkin, A., Kennedy, S., Connolly, L., Ballot, J., Ooi, W., et al. (2009). Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urology, 9, 6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Hu, J., Guan, W., Liu, P., Dai, J., Tang, K., Xiao, H., et al. (2017). Endoglin is essential for the maintenance of self-renewal and chemoresistance in renal cancer stem cells. Stem Cell Reports, 9(2), 464–477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Vogelzang, N. J., Priest, E. R., & Borden, L. (1992). Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: A case with 5-year followup. The Journal of Urology, 148(4), 1247–1248.

    Article  CAS  PubMed  Google Scholar 

  12. Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., et al. (2001). Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Research, 61(13), 5132–5136.

    CAS  PubMed  Google Scholar 

  13. Komohara, Y., Hasita, H., Ohnishi, K., Fujiwara, Y., Suzu, S., Eto, M., et al. (2011). Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Science, 102(7), 1424–1431.

    Article  CAS  PubMed  Google Scholar 

  14. Fisher, R. I., Rosenberg, S. A., & Fyfe, G. (2000). Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. The Cancer Journal from Scientific American, 6(Suppl 1), S55–S57.

    PubMed  Google Scholar 

  15. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995). Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of Clinical Oncology, 13(3), 688–696.

    Article  CAS  PubMed  Google Scholar 

  16. McDermott, D. F., Cheng, S. C., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., et al. (2015). The high-dose aldesleukin “select” trial: A trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clinical Cancer Research, 21(3), 561–568.

    Article  CAS  PubMed  Google Scholar 

  17. Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., et al. (2003). Randomized study of high-dose and low-dose inter leukin-2 in patients with metastatic renal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21(16), 3127.

    Article  CAS  Google Scholar 

  18. Clark, J. I., Wong, M. K., Kaufman, H. L., Daniels, G. A., Morse, M. A., McDermott, D. F., et al. (2017). Impact of sequencing targeted therapies with high-dose interleukin-2 immunotherapy: An analysis of outcome and survival of patients with metastatic renal cell carcinoma from an on-going observational IL-2 clinical trial: PROCLAIMSM. Clinical Genitourinary Cancer, 15(1), 31–41. e4.

    Article  PubMed  Google Scholar 

  19. Stenehjem, D. D., Toole, M., Merriman, J., Parikh, K., Daignault, S., Scarlett, S., et al. (2016). Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunology, Immunotherapy, 65(8), 941–949.

    Article  CAS  PubMed  Google Scholar 

  20. Collaborators MRCRC. (1999). Interferon-α and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. The Lancet, 353(9146), 14–17.

    Article  Google Scholar 

  21. Motzer, R. J. (2016). Perspective: What next for treatment? Nature, 537(7620), S111.

    Article  CAS  PubMed  Google Scholar 

  22. Albiges, L., Oudard, S., Negrier, S., Caty, A., Gravis, G., Joly, F., et al. (2012). Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. Journal of Clinical Oncology, 30(5), 482–487.

    Article  CAS  PubMed  Google Scholar 

  23. Yip, S. M., Wells, C., Moreira, R., Wong, A., Srinivas, S., Beuselinck, B., et al. (2018). Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium. Cancer, 124(18), 3677–3683.

    Article  CAS  PubMed  Google Scholar 

  24. Harshman, L. C., Drake, C. G., & Choueiri, T. K. (2014). PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunology Research, 2(12), 1132–1141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Teng, M. W., Swann, J. B., Koebel, C. M., Schreiber, R. D., & Smyth, M. J. (2008). Immune-mediated dormancy: An equilibrium with cancer. Journal of Leukocyte Biology, 84(4), 988–993.

    Article  CAS  PubMed  Google Scholar 

  26. Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21(2), 137–148.

    Article  CAS  PubMed  Google Scholar 

  27. Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011). Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science (New York, N.Y.), 331(6024), 1565–1570.

    Article  CAS  Google Scholar 

  28. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.

    Article  CAS  PubMed  Google Scholar 

  29. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine, 8(8), 793–800.

    Article  CAS  PubMed  Google Scholar 

  30. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., et al. (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine, 2(10), 1096–1103.

    Article  CAS  PubMed  Google Scholar 

  31. Gabrilovich, D. I., Ciernik, I. F., & Carbone, D. P. (1996). Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cellular Immunology, 170(1), 101–110.

    Article  CAS  PubMed  Google Scholar 

  32. Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., et al. (2012). Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science Translational Medicine, 4(127), 127ra37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Woo, S. R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., et al. (2012). Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Research, 72(4), 917–927.

    Article  CAS  PubMed  Google Scholar 

  34. Abou Alaiwi, S., Xie, W., Nassar, A. H., Dudani, S., Martini, D., Bakouny, Z., et al. (2020). Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. Journal for Immunotherapy of Cancer, 8(1), e000144.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Brahmer, J. R., Hammers, H., & Lipson, E. J. (2015). Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future Oncology, 11(9), 1307–1326.

    Article  CAS  PubMed  Google Scholar 

  36. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443–2454.

    Article  CAS  Google Scholar 

  37. Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology, 28(19), 3167.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., et al. (2015). Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. Journal of Clinical Oncology, 33(13), 1430–1437.

    Article  CAS  PubMed  Google Scholar 

  39. Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., et al. (2015). Nivolumab versus everolimus in advanced renal-cell carcinoma. The New England Journal of Medicine, 373(19), 1803–1813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet (London, England), 372(9637), 449–456.

    Article  CAS  Google Scholar 

  41. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine, 356(2), 115–124.

    Article  CAS  PubMed  Google Scholar 

  42. Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., et al. (2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet (London, England), 378(9807), 1931–1939.

    Article  CAS  Google Scholar 

  43. Cella, D., Grunwald, V., Nathan, P., Doan, J., Dastani, H., Taylor, F., et al. (2016). Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: A randomised, open-label, phase 3 trial. The Lancet Oncology, 17(7), 994–1003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Bilen, M. A., Dutcher, G. M. A., Liu, Y., Ravindranathan, D., Kissick, H. T., Carthon, B. C., et al. (2018). Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab. Clinical Genitourinary Cancer, 16(3), e563–e575.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Tannir, N. M., Frontera, O. A., Hammers, H. J., Carducci, M. A., McDermott, D. F., Salman, P., et al. (2019). Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab+ ipilimumab (N+ I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). American Society of Clinical Oncology, 37, 547–547.

    Article  Google Scholar 

  46. Cella, D., Grunwald, V., Escudier, B., Hammers, H. J., George, S., Nathan, P., et al. (2019). Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): A randomised, phase 3 trial. The Lancet Oncology, 20(2), 297–310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. McDermott, D. F., Lee, J.-L., Szczylik, C., Donskov, F., Malik, J., Alekseev, B. Y., et al. (2018). Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. American Society of Clinical Oncology, 36, 4500–4500.

    Article  Google Scholar 

  48. Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., et al. (2013). Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: A randomised open-label phase 3 trial. The Lancet Oncology, 14(13), 1287–1294.

    Article  CAS  PubMed  Google Scholar 

  49. Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C., et al. (2018). Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. The Lancet Oncology, 19(3), 405–415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., et al. (2019). Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. The New England Journal of Medicine, 380(12), 1116–1127.

    Article  CAS  PubMed  Google Scholar 

  51. Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., et al. (2019). Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. The New England Journal of Medicine, 380(12), 1103–1115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. McDermott, D., Atkins, M., Motzer, R., Rini, B., Escudier, B., Fong, L., et al. (Eds.) (2017). A phase II study of atezolizumab with or without bevacizumab vs. sunitnib in untreated metastatic renal cell carcinoma patients. 2017 Genitourinary Cancer Symposium (ASCO GU).

    Google Scholar 

  53. Motzer, R. J., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., et al. (2018). IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology, 36, 578–578.

    Article  Google Scholar 

  54. Rini, B. I., Motzer, R. J., Powles, T., McDermott, D. F., Escudier, B., Donskov, F., et al. (2020). Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: A prespecified subgroup analysis of the IMmotion151 clinical trial. European Urology, 79, 659–662.

    Article  PubMed  CAS  Google Scholar 

  55. Motzer, R., Choueiri, T. K., Powles, T., Burotto, M., Bourlon, M. T., Hsieh, J., et al. (Eds.). (2021). Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. Genitourinary Cancers Symposium. Journal of Clinical Oncology, 39(suppl 6; abstr), 308.

    Google Scholar 

  56. Motzer, R., Alekseev, B., Rha, S. Y., Porta, C., Eto, M., Powles, T., et al. (2021). Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. The New England Journal of Medicine, 384(14), 1289–1300.

    Article  CAS  PubMed  Google Scholar 

  57. Chowdhury, S., McDermott, D. F., Voss, M. H., Hawkins, R. E., Aimone, P., Voi, M., et al. (2017). A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). American Society of Clinical Oncology, 35(15_suppl), 4506–4506.

    Article  Google Scholar 

  58. Amin, A., Plimack, E. R., Ernstoff, M. S., Lewis, L. D., Bauer, T. M., McDermott, D. F., et al. (2018). Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study. Journal for Immunotherapy of Cancer, 6(1), 109.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Knox, J. J., et al. (2015). Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Journal for Immunotherapy of Cancer, 3, 14.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Figlin, R. A., Tannir, N. M., Uzzo, R. G., Tykodi, S. S., Chen, D. Y. T., Master, V., et al. (2020). Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clinical Cancer Research, 26(10), 2327–2336.

    Article  CAS  PubMed  Google Scholar 

  61. Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., et al. (2012). Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, 18(8), 1254.

    Article  CAS  PubMed  Google Scholar 

  62. Rini, B. I., Stenzl, A., Zdrojowy, R., Kogan, M., Shkolnik, M., Oudard, S., et al. (2016). IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): A multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Oncology, 17(11), 1599–1611.

    Article  CAS  PubMed  Google Scholar 

  63. Margolin, K., Aronson, F. R., Sznol, M., Atkins, M. B., Gucalp, R., Fisher, R. I., et al. (1994). Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. Journal of Immunotherapy with Emphasis on Tumor Immunology: Official Journal of the Society for Biological Therapy, 15(2), 147–153.

    Article  CAS  Google Scholar 

  64. Weiss, G. R., Margolin, K. A., Sznol, M., Atkins, M. B., Oleksowicz, L., Isaacs, R., et al. (1995). A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. Journal of Immunotherapy with Emphasis on Tumor Immunology: Official Journal of the Society for Biological Therapy, 18(1), 52–56.

    Article  CAS  Google Scholar 

  65. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., et al. (1997). Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clinical Cancer Research, 3(3), 409–417.

    CAS  PubMed  Google Scholar 

  66. Motzer, R. J., Rakhit, A., Schwartz, L. H., Olencki, T., Malone, T. M., Sandstrom, K., et al. (1998). Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clinical Cancer Research, 4(5), 1183–1191.

    CAS  PubMed  Google Scholar 

  67. Gollob, J. A., Veenstra, K. G., Parker, R. A., Mier, J. W., McDermott, D. F., Clancy, D., et al. (2003). Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. Journal of Clinical Oncology, 21(13), 2564–2573.

    Article  PubMed  CAS  Google Scholar 

  68. Charych, D. H., Hoch, U., Langowski, J. L., Lee, S. R., Addepalli, M. K., Kirk, P. B., et al. (2016). NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clinical Cancer Research, 22(3), 680–690.

    Article  CAS  PubMed  Google Scholar 

  69. Diab, A., Hurwitz, M. E., Cho, D. C., Papadimitrakopoulou, V., Curti, B. D., Tykodi, S. S., et al. (2018). NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. Journal of Clinical Oncology, 36(15_suppl), 3006.

    Article  Google Scholar 

  70. Naing, A., Wong, D. J., Infante, J. R., Korn, W. M., Aljumaily, R., Papadopoulos, K. P., et al. (2019). Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): A multicentre, multicohort, open-label, phase 1b trial. The Lancet Oncology, 20(11), 1544–1555.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Rausch, M., Hua, J., Moodley, D., White, K. F., Walsh, K. H., Miller, C. E., et al. (2020). Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting. Cancer Research, 80(16 Supplement), 4550.

    Article  Google Scholar 

  72. Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., et al. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research, 17(13), 4550–4557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Markel, G., Cohen-Sinai, T., Besser, M. J., Oved, K., Itzhaki, O., Seidman, R., et al. (2009). Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Research, 29(1), 145–154.

    CAS  PubMed  Google Scholar 

  74. Baldan, V., Griffiths, R., Hawkins, R. E., & Gilham, D. E. (2015). Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. British Journal of Cancer, 112(9), 1510.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Andersen, R., Donia, M., Westergaard, M. C. W., Pedersen, M., Hansen, M., & Svane, I. M. (2015). Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. Human Vaccines & Immunotherapeutics, 11(12), 2790–2795.

    Article  Google Scholar 

  76. Srivastava, S., & Riddell, S. R. (2015). Engineering CAR-T cells: Design concepts. Trends in Immunology, 36(8), 494–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., et al. (2015). 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature Medicine, 21(6), 581–590.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Lamers, C. H., Sleijfer, S., Van Steenbergen, S., Van Elzakker, P., Van Krimpen, B., Groot, C., et al. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity. Molecular Therapy, 21(4), 904–912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Tafreshi, N. K., Lloyd, M. C., Bui, M. M., Gillies, R. J., & Morse, D. L. (2014). Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. In Carbonic anhydrase: Mechanism, regulation, links to disease, and industrial applications (pp. 221–254). Springer.

    Chapter  Google Scholar 

  80. Pastorekova, S., Parkkila, S., Parkkila, A. K., Opavsky, R., Zelnik, V., Saarnio, J., et al. (1997). Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology, 112(2), 398–408.

    Article  CAS  PubMed  Google Scholar 

  81. Weijtens, M. E., Willemsen, R. A., Valerio, D., Stam, K., & Bolhuis, R. (1996). Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. The Journal of Immunology, 157(2), 836–843.

    Article  CAS  PubMed  Google Scholar 

  82. Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., et al. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. Journal of Clinical Oncology, 24(13), e20–ee2.

    Article  PubMed  Google Scholar 

  83. Wang, Q. J., Yu, Z., Hanada, K.-I., Patel, K., Kleiner, D., Restifo, N. P., et al. (2017). Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers. Clinical Cancer Research, 23(9), 2267–2276.

    Article  CAS  PubMed  Google Scholar 

  84. Finke, J. H., Rayman, P. A., Ko, J. S., Bradley, J. M., Gendler, S. J., & Cohen, P. A. (2013). Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer Journal (Sudbury, Mass), 19(4), 353–364.

    Article  CAS  Google Scholar 

  85. Rodriguez, P. C., Zea, A. H., Culotta, K. S., Zabaleta, J., Ochoa, J. B., & Ochoa, A. C. (2002). Regulation of t cell receptor cd3ζ chain expression byl-arginine. Journal of Biological Chemistry, 277(24), 21123–21129.

    Article  CAS  Google Scholar 

  86. Cesana, G. C., DeRaffele, G., Cohen, S., Moroziewicz, D., Mitcham, J., Stoutenburg, J., et al. (2006). Characterization of CD4+ CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. Journal of Clinical Oncology, 24(7), 1169–1177.

    Article  CAS  PubMed  Google Scholar 

  87. Siddiqui, S. A., Frigola, X., Bonne-Annee, S., Mercader, M., Kuntz, S. M., Krambeck, A. E., et al. (2007). Tumor-infiltrating Foxp3− CD4+ CD25+ T cells predict poor survival in renal cell carcinoma. Clinical Cancer Research, 13(7), 2075–2081.

    Article  CAS  PubMed  Google Scholar 

  88. Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., et al. (2009). Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clinical Cancer Research, 15(6), 2148–2157.

    Article  CAS  PubMed  Google Scholar 

  89. Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., et al. (2008). Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clinical Cancer Research, 14(20), 6674–6682.

    Article  CAS  PubMed  Google Scholar 

  90. Yeku, O., Li, X., & Brentjens, R. J. (2017). Adoptive T-cell therapy for solid tumors. American Society of Clinical Oncology Educational Book, 37, 193–204.

    Article  PubMed  Google Scholar 

  91. Messing, E. M., Manola, J., Wilding, G., Propert, K., Fleischmann, J., Crawford, E. D., et al. (2003). Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An eastern cooperative oncology group/intergroup trial. Journal of Clinical Oncology, 21(7), 1214–1222.

    Article  CAS  PubMed  Google Scholar 

  92. Clark, J. I., Atkins, M. B., Urba, W. J., Creech, S., Figlin, R. A., Dutcher, J. P., et al. (2003). Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. Journal of Clinical Oncology, 21(16), 3133–3140.

    Article  CAS  PubMed  Google Scholar 

  93. Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., et al. (2004). Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet (London, England), 363(9409), 594–599.

    Article  CAS  Google Scholar 

  94. Jonasch, E., Wood, C., Tamboli, P., Pagliaro, L. C., Tu, S. M., Kim, J., et al. (2008). Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: Clinical findings. British Journal of Cancer, 98(8), 1336–1341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Wood, C., Srivastava, P., Bukowski, R., Lacombe, L., Gorelov, A. I., Gorelov, S., et al. (2008). An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial. Lancet (London, England), 372(9633), 145–154.

    Article  CAS  Google Scholar 

  96. López, J. I., Pulido, R., Cortés, J. M., Angulo, J. C., & Lawrie, C. H. (2018). Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. Pathology Research and Practice, 214(8), 1110–1114.

    Article  CAS  Google Scholar 

  97. Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017). Tumor mutational burden and response rate to PD-1 inhibition. New England Journal of Medicine, 377(25), 2500–2501.

    Article  Google Scholar 

  98. Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., et al. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.), 348(6230), 124–128.

    Article  CAS  PubMed Central  Google Scholar 

  99. De Velasco, G., Miao, D., Voss, M. H., Hakimi, A. A., Hsieh, J. J., Tannir, N. M., et al. (2016). Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups. Cancer Immunology Research, 4(10), 820–822.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Malouf, G. G., Ali, S. M., Wang, K., Balasubramanian, S., Ross, J. S., Miller, V. A., et al. (2016). Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. European Urology, 70(2), 348–357.

    Article  CAS  PubMed  Google Scholar 

  101. de Velasco, G., Miao, D., Shukla, S., Voss, M. H., Wu, C., Murray, B., et al. (2016). Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology, 34(2_suppl), 545–545.

    Article  Google Scholar 

  102. Rini, B., Huseni, M., Atkins, M., McDermott, M., Powles, T., Escudier, B., et al. (Eds.). (2018). Molecular correlates differentiate response to atezolizumab (atezo)+ bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Abstract LBA31 Presented at: ESMO Annual Meeting, Genitourinary Cancers/Cancer Immunology and Immunotherapy/Anticancer Agents & Biologic Therapy Munich, Germany.

    Google Scholar 

  103. Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., et al. (2020). Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: Biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nature Medicine, 26(11), 1733–1741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: a Cancer Journal for Clinicians, 69(1), 7–34.

    Google Scholar 

  105. Athanazio, D. A., & Trpkov, K. (2016). What is new in genitourinary pathology? Recent developments and highlights of the new 2016 World Health Organization classification of tumors of the urinary system and male genital organs. Applied Cancer Research, 36(1), 1.

    Article  Google Scholar 

  106. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87–108.

    Google Scholar 

  107. NIH NCI. Surveillance E, and End Results Program. Cancer Stat Facts: Bladder Cancer 2018. Available from: https://seer.cancer.gov/statfacts/html/urinb.html

  108. Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., et al. (2016). Bladder cancer. The Lancet, 388(10061), 2796–2810.

    Article  Google Scholar 

  109. Pasin, E., Josephson, D. Y., Mitra, A. P., Cote, R. J., & Stein, J. P. (2008). Superficial bladder cancer: An update on etiology, molecular development, classification, and natural history. Reviews in Urology, 10(1), 31–43.

    PubMed  PubMed Central  Google Scholar 

  110. NCI. Surveillance, epidemiology, and end results program. Cancer Stat Facts: Bladder Cancer 2018. Available from: https://seer.cancer.gov/statfacts/html/urinb.html

  111. von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., et al. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology, 18(17), 3068–3077. (0732-183X (Print)).

    Article  PubMed  Google Scholar 

  112. Galsky, M. D., Mironov, S., Iasonos, A., Scattergood, J., Boyle, M. G., & Bajorin, D. F. (2007). Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Investigational New Drugs, 25(3), 265–270.

    Article  CAS  PubMed  Google Scholar 

  113. Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002). Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Journal of Clinical Oncology, 20(4), 937–940.

    Article  CAS  PubMed  Google Scholar 

  114. Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., et al. (2018). Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): Pooled results from two expansion cohorts of an open-label, phase 1 trial. The Lancet Oncology, 19(1), 51–64.

    Article  CAS  PubMed  Google Scholar 

  115. Powles, T., O’Donnell, P. H., Massard, C., et al. (2017). Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study. JAMA Oncology, 3(9), e172411.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., et al. (2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. The Lancet, 387(10031), 1909–1920.

    Article  CAS  Google Scholar 

  117. Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., et al. (2016). Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet Oncology, 17(11), 1590–1598.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., et al. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 515, 558.

    Article  CAS  PubMed  Google Scholar 

  119. Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., et al. (2017). Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. Journal of Clinical Oncology, 35(19), 2117–2124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Balar, A. V., Castellano, D., O’Donnell, P. H., Grivas, P., Vuky, J., Powles, T., et al. (2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. The Lancet Oncology, 18(11), 1483–1492.

    Article  CAS  PubMed  Google Scholar 

  121. Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., et al. (2017). Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New England Journal of Medicine, 376(11), 1015–1026.

    Article  CAS  Google Scholar 

  122. Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., et al. (2013). Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(25), 3133–3140.

    Article  CAS  Google Scholar 

  123. Nagayama, A., Ellisen, L. W., Chabner, B., & Bardia, A. (2017). Antibody-drug conjugates for the treatment of solid tumors: Clinical experience and latest developments. Targeted Oncology, 12(6), 719–739.

    Article  PubMed  Google Scholar 

  124. Alhalabi, O., Rafei, H., Shah, A., Siefker-Radtke, A., Campbell, M., & Gao, J. (2019). Targeting advanced urothelial carcinoma-developing strategies. Current Opinion in Oncology, 31(3), 207–215.

    Article  PubMed  Google Scholar 

  125. Morales, A., Eidinger, D., & Bruce, A. W. (1976). Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. The Journal of Urology, 116(2), 180–183.

    Article  CAS  PubMed  Google Scholar 

  126. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013). Signatures of mutational processes in human cancer. Nature, 500, 415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. The Cancer Genome Atlas Research N. (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315.

    Article  CAS  Google Scholar 

  128. Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230), 124–128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., et al. (2018). Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. New England Journal of Medicine, 378(22), 2093–2104.

    Article  CAS  Google Scholar 

  130. Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69.

    Article  CAS  PubMed  Google Scholar 

  131. Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007). Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunology, Immunotherapy, 56(8), 1173–1182.

    Article  CAS  PubMed  Google Scholar 

  132. Boorjian, S. A., Sheinin, Y., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., et al. (2008). T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival. Clinical Cancer Research, 14(15), 4800.

    Article  CAS  PubMed  Google Scholar 

  133. Xylinas, E., Robinson, B. D., Kluth, L. A., Volkmer, B. G., Hautmann, R., Kufer, R., et al. (2014). Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40(1), 121–127.

    Article  CAS  Google Scholar 

  134. Brown, J. T., Liu, Y., Shabto, J. M., Martini, D. J., Ravindranathan, D., Hitron, E. E., et al. (2021). Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial cell carcinoma treated with immune checkpoint inhibitors. The Oncologist, 26(5), 397–405.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Shabto, J. M., Martini, D. J., Liu, Y., Ravindranathan, D., Brown, J., Hitron, E. E., et al. (2020). Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. Cancer Medicine, 9(8), 2752–2760.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Herr, H. W., & Sogani, P. C. (2001). Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? The Journal of Urology, 166(4), 1296–1299.

    Article  CAS  PubMed  Google Scholar 

  137. Lamm, D. L., Thor, D. E., Harris, S. C., Reyna, J. A., Stogdill, V. D., & Radwin, H. M. (1980). Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. The Journal of Urology, 124(1), 38–40.

    Article  CAS  PubMed  Google Scholar 

  138. Pettenati, C., & Ingersoll, M. A. (2018). Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nature Reviews Urology, 15(10), 615–625.

    Article  CAS  PubMed  Google Scholar 

  139. Bohle, A., Jocham, D., & Bock, P. R. (2003). Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. The Journal of Urology, 169(1), 90–95.

    Article  CAS  PubMed  Google Scholar 

  140. Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., et al. (2001). A systematic review of intravesical Bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU International, 88(3), 209–216.

    Article  CAS  PubMed  Google Scholar 

  141. Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004). Intravesical Bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials. BJU International, 93(4), 485–490.

    Article  CAS  PubMed  Google Scholar 

  142. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A., et al. (2000). Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. The Journal of Urology, 163(4), 1124–1129.

    Article  CAS  PubMed  Google Scholar 

  143. Singh, P., Catherine, T., Lerner, S. P., McConkey, D., Plets, M., Lucia, M. S., et al. (2017). S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer. Journal of Clinical Oncology, 35(15_suppl), TPS4591-TPS.

    Article  Google Scholar 

  144. Balar, A. V., Kulkarni, G. S., Uchio, E. M., Boormans, J., Mourey, L., Krieger, L. E. M., et al. (2019). Keynote 057: Phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). Journal of Clinical Oncology, 37(7_suppl), 350.

    Article  Google Scholar 

  145. Solsona, E., Iborra, I., Collado, A., Rubio-Briones, J., Casanova, J., & Calatrava, A. (2010). Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. The Journal of Urology, 184(2), 475–480.

    Article  PubMed  Google Scholar 

  146. Leibovici, D., Kassouf, W., Pisters, L. L., Pettaway, C. A., Wu, X., Dinney, C. P., et al. (2007). Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology, 70(3), 473–476.

    Article  PubMed  Google Scholar 

  147. Vale, C. L. (2005). Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European Urology, 48(2), 202–205. discussion 5–6.

    Article  Google Scholar 

  148. Balducci, L., & Extermann, M. (2000). Management of cancer in the older person: A practical approach. The Oncologist, 5(3), 224–237.

    Article  CAS  PubMed  Google Scholar 

  149. Boyd, C. M., Darer, J., Boult, C., Fried, L. P., Boult, L., & Wu, A. W. (2005). Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. JAMA, 294(6), 716–724.

    Article  CAS  PubMed  Google Scholar 

  150. Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., et al. (2010). Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical Cancer Research, 16(10), 2861.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., et al. (2018). Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study. Journal of Clinical Oncology, 36(34), 3353–3360.

    Article  CAS  PubMed  Google Scholar 

  152. Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., et al. (2018). Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. The Lancet, 391(10122), 748–757.

    Article  CAS  Google Scholar 

  153. Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., et al. (2020). Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine, 26(12), 1845–1851.

    Article  CAS  PubMed  Google Scholar 

  154. Grande, E., Guerrero, F., Puente, J., Galante, I., Duran, I., Dominguez, M., et al. (2020). DUTRENEO trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. Journal of Clinical Oncology, 38(15_suppl), 5012.

    Article  Google Scholar 

  155. Weickhardt, A. J., Foroudi, F., Sengupta, S., Galletta, L., Herschtal, A., Grimison, P. S., et al. (2018). Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial. Journal of Clinical Oncology, 36(6_suppl), TPS531-TPS.

    Article  Google Scholar 

  156. Bajorin, D. F., Witjes, J. A., Gschwend, J., Schenker, M., Valderrama, B. P., Tomita, Y., et al. (Eds.). (2021). First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). Genitourinary Cancers Symposium. Journal of Clinical Oncology, 39(suppl 6; abstr), 391.

    Google Scholar 

  157. Hussain, M. H. A., Powles, T., Albers, P., Castellano, D., Daneshmand, S., Gschwend, J., et al. (2020). IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). Journal of Clinical Oncology, 38(15_suppl), 5000.

    Article  Google Scholar 

  158. NIH. (2018). U.S. National Library of Medicine. ClinicalTrials.gov. Available from: U.S. National Library of Medicine. ClinicalTrials.gov

  159. Powles, T., Gschwend, J. E., Loriot, Y., Bellmunt, J., Geczi, L., Vulsteke, C., et al. (2017). Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. Journal of Clinical Oncology, 35(15_suppl), TPS4590-TPS.

    Article  Google Scholar 

  160. Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., et al. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. The Lancet, 389(10064), 67–76.

    Article  CAS  Google Scholar 

  161. Galsky, M. D., Grande, E., Davis, I. D., De Santis, M., Arranz Arija, J. A., Kikuchi, E., et al. (2018). IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology, 36(15_suppl), TPS4589-TPS.

    Article  Google Scholar 

  162. Plimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J., et al. (2017). Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. The Lancet Oncology, 18(2), 212–220.

    Article  CAS  PubMed  Google Scholar 

  163. Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., et al. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. The Lancet Oncology, 18(3), 312–322.

    Article  CAS  PubMed  Google Scholar 

  164. Boyerinas, B., Jochems, C., Fantini, M., Heery, C. R., Gulley, J. L., Tsang, K. Y., et al. (2015). Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunology Research, 3(10), 1148.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., et al. (2016). Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. Journal of Clinical Oncology, 34(26), 3119–3125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Apolo, A. B. (2016). PDL1: The illusion of an ideal biomarker. European Urology Focus, 1(3), 269–271.

    Article  PubMed  Google Scholar 

  167. Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., et al. (2016). Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell, 167(2), 397–404.e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. New England Journal of Medicine, 375(9), 819–829.

    Article  CAS  Google Scholar 

  169. Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., et al. (2016). Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discovery, 7(2), 188–201.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  170. Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., et al. (2017). Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Reports, 19(6), 1189–1201.

    Article  CAS  PubMed  Google Scholar 

  171. Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., et al. (2017). Identification of essential genes for cancer immunotherapy. Nature, 548, 537.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Fujii, T., Naing, A., Rolfo, C., & Hajjar, J. (2018). Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 130, 108–120.

    Article  PubMed  Google Scholar 

  173. Pichler, R., Heidegger, I., Fritz, J., Danzl, M., Sprung, S., Zelger, B., et al. (2017). PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget, 8(40), 66849–66864.

    Article  PubMed  PubMed Central  Google Scholar 

  174. Powles, T., van der Heijden, M. S., Castellano, D., Galsky, M. D., Loriot, Y., Petrylak, D. P., et al. (2020). Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): A randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology, 21(12), 1574–1588.

    Article  CAS  PubMed  Google Scholar 

  175. Galsky, M. D., Powles, T., Li, S., Hennicken, D., & Sonpavde, G. (2018). A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901). Journal of Clinical Oncology, 36(6_suppl), TPS539-TPS.

    Article  Google Scholar 

  176. Galsky, M. D., Arija, J. A. A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., et al. (2020). Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 395(10236), 1547–1557.

    Article  CAS  PubMed  Google Scholar 

  177. Alva, A. S., McDaniel, A., Zhan, T., Xiao, H., Chinnaiyan, A. M., Lee, C. T., et al. (2015). Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma. Journal of Clinical Oncology, 33(7_suppl), 313.

    Article  Google Scholar 

  178. Hoimes, C. J., Rosenberg, J. E., Petrylak, D. P., Carret, A.-S., Melhem-Bertrandt, A., & Flaig, T. W. (2019). EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer. Journal of Clinical Oncology, 37(15_suppl), TPS4593-TPS.

    Article  Google Scholar 

  179. Lan, Y. Z. D., Xu, C., Marelli, B., Qi, J., Qi, H., et al. (Eds.). (2017). Preclinical evaluation and mechanistic characterization of M7824 (MSB0011359C), a novel bifunctional fusion protein targeting the PD-L1 and TGFβ pathways. AACR 2017 Annual Meeting, April 1–5, 2017, Washington, DC.

    Google Scholar 

  180. Gulley, J. L., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Lamping, E., et al. (2017). Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors. Journal of Clinical Oncology, 35(15_suppl), 3006.

    Article  Google Scholar 

  181. Siefker-Radtke, A. O., Fishman, M. N., Balar, A. V., Grignani, G., Diab, A., Gao, J., et al. (2019). NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02. Journal of Clinical Oncology, 37(7_suppl), 388.

    Article  Google Scholar 

  182. Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7–30.

    Google Scholar 

  183. Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer statistics, 2017. CA: A Cancer Journal for Clinicians, 67(1), 7–30.

    Google Scholar 

  184. Fedewa, S. A., Ward, E. M., Brawley, O., & Jemal, A. (2017). Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Internal Medicine, 177(7), 1040–1042.

    Article  PubMed  PubMed Central  Google Scholar 

  185. Hu, J. C., Nguyen, P., Mao, J., Halpern, J., Shoag, J., Wright, J. D., et al. (2017). Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncology, 3(5), 705–707.

    Article  PubMed  Google Scholar 

  186. Loblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., et al. (2007). Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology Practice Guideline. Journal of Clinical Oncology, 25(12), 1596–1605.

    Article  CAS  PubMed  Google Scholar 

  187. James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., et al. (2017). Abiraterone for prostate Cancer not previously treated with hormone therapy. The New England Journal of Medicine, 377(4), 338–351.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., et al. (2017). Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. The New England Journal of Medicine, 377(4), 352–360.

    Article  CAS  PubMed  Google Scholar 

  189. James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., et al. (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet (London, England), 387(10024), 1163–1177.

    Article  CAS  Google Scholar 

  190. Sweeney, C. J., Chen, Y. H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., et al. (2015). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. The New England Journal of Medicine, 373(8), 737–746.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  191. Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., et al. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. The New England Journal of Medicine, 381(2), 121–131.

    Article  CAS  PubMed  Google Scholar 

  192. Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., et al. (2019). Apalutamide for metastatic, castration-sensitive prostate cancer. The New England Journal of Medicine, 381(1), 13–24.

    Article  CAS  PubMed  Google Scholar 

  193. Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., et al. (2017). Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precision Oncology, 2017, PO.17.00029.

    Google Scholar 

  194. Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine, 368(2), 138–148.

    Article  CAS  PubMed  Google Scholar 

  195. Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367(13), 1187–1197.

    Article  CAS  PubMed  Google Scholar 

  196. Fizazi, K., Scher, H. I., Miller, K., Basch, E., Sternberg, C. N., Cella, D., et al. (2014). Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial. The Lancet Oncology, 15(10), 1147–1156.

    Article  CAS  PubMed  Google Scholar 

  197. Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Fossa, S. D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine, 369(3), 213–223.

    Article  CAS  PubMed  Google Scholar 

  198. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 363(5), 411–422.

    Article  CAS  Google Scholar 

  199. de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet (London, England), 376(9747), 1147–1154.

    Article  CAS  Google Scholar 

  200. Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(2), 242–245.

    Article  CAS  Google Scholar 

  201. McNeel, D. G., Bander, N. H., Beer, T. M., Drake, C. G., Fong, L., Harrelson, S., et al. (2016). The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. Journal for Immunotherapy of Cancer, 4(1), 92.

    Article  PubMed  PubMed Central  Google Scholar 

  202. Attard, G., Parker, C., Eeles, R. A., Schroder, F., Tomlins, S. A., Tannock, I., et al. (2016). Prostate cancer. Lancet (London, England), 387(10013), 70–82.

    Article  Google Scholar 

  203. Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998). Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer, 82(11), 2256–2261.

    Article  CAS  PubMed  Google Scholar 

  204. Riegman, P. H. J., Vlietstra, R. J., van der Korput, J. A. G. M., Romijn, J. C., & Trapman, J. (1989). Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. Biochemical and Biophysical Research Communications, 159(1), 95–102.

    Article  CAS  PubMed  Google Scholar 

  205. Solin, T., Kontturi, M., Pohlmann, R., & Vihko, P. (1990). Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1048(1), 72–77.

    Article  CAS  Google Scholar 

  206. Coffey, D. S., & Isaacs, J. T. (1981). Prostate tumor biology and cell kinetics – Theory. Urology, 17(Suppl 3), 40–53.

    CAS  PubMed  Google Scholar 

  207. Olson, B. M., & McNeel, D. G. (2011). CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunology, Immunotherapy: CII, 60(6), 781–792.

    Article  CAS  PubMed  Google Scholar 

  208. Hadaschik, B., Su, Y., Huter, E., Ge, Y., Hohenfellner, M., & Beckhove, P. (2012). Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer. The Journal of Urology, 187(4), 1458–1465.

    Article  CAS  PubMed  Google Scholar 

  209. Chakraborty, N. G., Stevens, R. L., Mehrotra, S., Laska, E., Taxel, P., Sporn, J. R., et al. (2003). Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunology, Immunotherapy: CII, 52(8), 497–505.

    Article  CAS  PubMed  Google Scholar 

  210. Peshwa, M. V., Shi, J. D., Ruegg, C., Laus, R., & van Schooten, W. C. (1998). Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. The Prostate, 36(2), 129–138.

    Article  CAS  PubMed  Google Scholar 

  211. Machlenkin, A., Paz, A., Bar Haim, E., Goldberger, O., Finkel, E., Tirosh, B., et al. (2005). Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Research, 65(14), 6435–6442.

    Article  CAS  PubMed  Google Scholar 

  212. Johnson, L. E., Frye, T. P., Chinnasamy, N., Chinnasamy, D., & McNeel, D. G. (2007). Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunology, Immunotherapy: CII, 56(6), 885–895.

    Article  CAS  PubMed  Google Scholar 

  213. Sfanos, K. S., Bruno, T. C., Meeker, A. K., De Marzo, A. M., Isaacs, W. B., & Drake, C. G. (2009). Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. The Prostate, 69(15), 1694–1703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Mercader, M., Bodner, B. K., Moser, M. T., Kwon, P. S., Park, E. S., Manecke, R. G., et al. (2001). T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 98(25), 14565–14570.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  215. Gannon, P. O., Poisson, A. O., Delvoye, N., Lapointe, R., Mes-Masson, A.-M., & Saad, F. (2009). Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. Journal of Immunological Methods, 348(1), 9–17.

    Article  CAS  PubMed  Google Scholar 

  216. Barach, Y. S., Lee, J. S., & Zang, X. (2011). T cell coinhibition in prostate cancer: New immune evasion pathways and emerging therapeutics. Trends in Molecular Medicine, 17(1), 47–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  217. Degl’Innocenti, E., Grioni, M., Boni, A., Camporeale, A., Bertilaccio, M. T. S., Freschi, M., et al. (2005). Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. European Journal of Immunology, 35(1), 66–75.

    Article  PubMed  CAS  Google Scholar 

  218. Madan, R. A., Gulley, J. L., & Kantoff, P. W. (2013). Demystifying immunotherapy in prostate cancer: Understanding current and future treatment strategies. Cancer Journal (Sudbury, Mass), 19(1), 50–58.

    Article  CAS  Google Scholar 

  219. Quinn, D. I., Shore, N. D., Egawa, S., Gerritsen, W. R., & Fizazi, K. (2015). Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urologic Oncology: Seminars and Original Investigations, 33(5), 245–260.

    Article  CAS  PubMed  Google Scholar 

  220. Goldman, B., & DeFrancesco, L. (2009). The cancer vaccine roller coaster. Nature Biotechnology, 27, 129.

    Article  CAS  PubMed  Google Scholar 

  221. Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J., Yuh, L., et al. (2009). Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer, 115(16), 3670–3679.

    Article  CAS  PubMed  Google Scholar 

  222. Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., et al. (2006). Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. Journal of Clinical Oncology, 24(19), 3089–3094.

    Article  CAS  PubMed  Google Scholar 

  223. Parker, C., Haynes, L., Huber, M. L., & Iversen, P. (2012). Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. Journal of the National Cancer Institute, 104(4), 273–279.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  224. Higano, C. S., Small, E. J., Whitmore, J. B., Frohlich, M. W., Schellhammer, P. F., & Kantoff, P. W. (2012). Re: Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. Journal of the National Cancer Institute, 104(14), 1107–1109.

    Article  PubMed  Google Scholar 

  225. Wargowski, E., Johnson, L. E., Eickhoff, J. C., Delmastro, L., Staab, M. J., Liu, G., et al. (2018). Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using sipuleucel-T and a DNA vaccine. Journal for Immunotherapy of Cancer, 6(1), 21.

    Article  PubMed  PubMed Central  Google Scholar 

  226. Petrylak, D. P., Drake, C. G., Pieczonka, C. M., Corman, J. M., Garcia, J. A., Dunshee, C., et al. (2018). Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study. Journal of Clinical Oncology, 36(6_suppl), 246.

    Article  Google Scholar 

  227. Small, E. J., Lance, R. S., Redfern, C. H., Millard, F. E., Gardner, T. A., Dawson, N. A., et al. (2017). Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts). Journal of Clinical Oncology, 35(6_suppl), 190.

    Article  Google Scholar 

  228. Strauss, J., Madan, R. A., & Figg, W. D. (2015). Evaluating immune responses after sipuleucel-T therapy. Cancer Biology & Therapy, 16(8), 1119–1121.

    Article  Google Scholar 

  229. Higano, C. S., Corman, J. M., Smith, D. C., Centeno, A. S., Steidle, C. P., Gittleman, M., et al. (2008). Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer, 113(5), 975–984.

    Article  CAS  PubMed  Google Scholar 

  230. Simons, J. W., Carducci, M. A., Mikhak, B., Lim, M., Biedrzycki, B., Borellini, F., et al. (2006). Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clinical Cancer Research, 12(11), 3394.

    Article  CAS  PubMed  Google Scholar 

  231. Sanda, M. G., Smith, D. C., Charles, L. G., Hwang, C., Pienta, K. J., Schlom, J., et al. (1999). Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 53(2), 260–266.

    Article  CAS  PubMed  Google Scholar 

  232. Eder, J. P., Kantoff, P. W., Roper, K., Xu, G. X., Bubley, G. J., Boyden, J., et al. (2000). A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 6(5), 1632–1638.

    CAS  Google Scholar 

  233. Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., et al. (2010). Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 28(7), 1099–1105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  234. Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., et al. (2018). Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. Journal of Clinical Oncology, 36(15_suppl), 5006.

    Article  Google Scholar 

  235. Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., et al. (2018). Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 37(13), JCO.18.02031.

    Google Scholar 

  236. Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell, 161(2), 205–214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  237. Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56.

    Article  CAS  PubMed  Google Scholar 

  238. Gulley, J. L., & Madan, R. A. (2018). Finding an immunologic beachhead in the prostate cancer microenvironment. Journal of the National Cancer Institute, 111(3), 219–220.

    PubMed Central  Google Scholar 

  239. Fizazi, K., Drake, C. G., Shaffer, D. R., Pachynski, R., Saad, F., Ciprotti, M., et al. (2018). An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD). Journal of Clinical Oncology, 36(15_suppl), TPS3126-TPS.

    Article  Google Scholar 

  240. Bendell, J., Bauer, T., Patel, M., Falchook, G., Karlix, J. L., Lim, E., et al. (2019). Abstract CT026: Evidence of immune activation in the first-in-human phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Cancer Research, 79(13 Supplement), CT026-CT.

    Article  Google Scholar 

  241. Scher, H. I., Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., et al. (2013). Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study. Annals of Oncology, 24(7), 1813–1821.

    Article  PubMed  PubMed Central  Google Scholar 

  242. Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., et al. (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology, 15(7), 700–712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  243. Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., et al. (2016). Randomized, double-blind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. Journal of Clinical Oncology, 35(1), 40–47.

    Article  PubMed  Google Scholar 

  244. Small, E., Higano, C., Tchekmedyian, N., Sartor, O., Stein, B., Young, R., et al. (2006). Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. Journal of Clinical Oncology, 24(18_suppl), 4609.

    Article  Google Scholar 

  245. Autio, K. A., Eastham, J. A., Danila, D. C., Slovin, S. F., Morris, M. J., Abida, W., et al. (2017). A phase II study combining ipilimumab and degarelix with or without radical prostatectomy (RP) in men with newly diagnosed metastatic noncastration prostate cancer (mNCPC) or biochemically recurrent (BR) NCPC. Journal of Clinical Oncology, 35(6_suppl), 203.

    Article  Google Scholar 

  246. Scholz, M., Yep, S., Chancey, M., Kelly, C., Chau, K., Turner, J., et al. (2017). Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. Immunotargets and Therapy, 6, 11–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  247. Hansen, A. R., Massard, C., Ott, P. A., Haas, N. B., Lopez, J. S., Ejadi, S., et al. (2018). Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29(8), 1807–1813.

    Article  CAS  Google Scholar 

  248. Bono, J. S. D., Goh, J. C., Ojamaa, K., Rodriguez, J. M. P., Drake, C. G., Hoimes, C. J., et al. (2018). KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 36(15_suppl), 5007.

    Article  Google Scholar 

  249. Graff, J. N., Alumkal, J. J., Drake, C. G., Thomas, G. V., Redmond, W. L., Farhad, M., et al. (2016). Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget, 7(33), 52810–52817.

    Article  PubMed  PubMed Central  Google Scholar 

  250. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509–2520.

    Article  CAS  Google Scholar 

  251. Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409–413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  252. Robinson, D., Van Allen, E. M., Wu, Y. M., Schultz, N., Lonigro, R. J., Mosquera, J. M., et al. (2015). Integrative clinical genomics of advanced prostate cancer. Cell, 161(5), 1215–1228.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  253. Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Rathkopf, D. E., et al. (2018). Microsatellite instability in prostate cancer and response to immune checkpoint blockade. Journal of Clinical Oncology, 36(15_suppl), 5020.

    Article  Google Scholar 

  254. Sharma, P., Pachynski, R. K., Narayan, V., Flechon, A., Gravis, G., Galsky, M. D., et al. (2019). Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). Journal of Clinical Oncology, 37(7_suppl), 142.

    Article  Google Scholar 

  255. Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 26(7), 1148–1159.

    Article  PubMed  Google Scholar 

  256. Fong, P. C. C., Retz, M., Drakaki, A., Massard, C., Berry, W. R., Romano, E., et al. (2019). Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 37(7_suppl), 171.

    Article  Google Scholar 

  257. Kolinsky, M. P., Gravis, G., Mourey, L., Piulats, J. M., Sridhar, S. S., Romano, E., et al. (2020). KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 38(6_suppl), 103.

    Article  Google Scholar 

  258. Yu, E. Y., Piulats, J. M., Gravis, G., Laguerre, B., Arija, J. A. A., Oudard, S., et al. (2020). KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 38(6_suppl), 100.

    Article  Google Scholar 

  259. Fizazi, K., Mella, P. G., Castellano, D., Minatta, J. N., Kalebasty, A. R., Shaffer, D., et al. (Eds.). (2019). Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD. ESMO 2019. Annals of Oncology, 30(suppl_5), v851–v934.

    Google Scholar 

  260. Powles, T., Fizazi, K., Gillessen, S., Drake, C. G., Rathkopf, D. E., Narayanan, S., et al. (2017). A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 35(15_suppl), TPS5090-TPS.

    Article  Google Scholar 

  261. Sweeney, C. J., Gillessen, S., Rathkopf, D., Matsubara, N., Drake, C., Fizazi, K., et al. (Eds.). (2020). IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). AACR Annual Meeting.

    Google Scholar 

  262. Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., et al. (2018). Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36(17), 1685–1694.

    Article  CAS  Google Scholar 

  263. Barber, G. N. (2015). STING: Infection, inflammation and cancer. Nature Reviews Immunology, 15(12), 760–770.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  264. Karzai, F., Madan, R. A., Owens, H., Couvillon, A., Hankin, A., Williams, M., et al. (2018). A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. Journal of Clinical Oncology, 36(6_suppl), 163.

    Article  Google Scholar 

  265. Karzai, F., VanderWeele, D., Madan, R. A., Owens, H., Cordes, L. M., Hankin, A., et al. (2018). Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. Journal for Immunotherapy of Cancer, 6(1), 141.

    Article  PubMed  PubMed Central  Google Scholar 

  266. Ghosh, A., & Heston, W. D. (2004). Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. Journal of Cellular Biochemistry, 91(3), 528–539.

    Article  CAS  PubMed  Google Scholar 

  267. Kim, Y. J., & Kim, Y.-I. (2018). Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: A meta-analysis. Clinical Nuclear Medicine, 43(10), 728–734.

    Article  PubMed  Google Scholar 

  268. Hofman, M. S., Emmett, L., Sandhu, S. K., Iravani, A., Joshua, A. M., Goh, J. C., et al. (2020). TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). Journal of Clinical Oncology, 38(15_suppl), 5500.

    Article  Google Scholar 

  269. Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., et al. (2008). Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 13(1), 23–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  270. Zuccolotto, G., Fracasso, G., Merlo, A., Montagner, I. M., Rondina, M., Bobisse, S., et al. (2014). PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS One, 9(10), e109427.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  271. Slovin, S. F., Wang, X., Hullings, M., Arauz, G., Bartido, S., Lewis, J. S., et al. (2013). Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). Journal of Clinical Oncology, 31(15_suppl), TPS3115-TPS.

    Article  Google Scholar 

  272. Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., et al. (2018). Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Molecular Therapy, 26(7), 1855–1866.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  273. Narayan, V., Gladney, W., Plesa, G., Vapiwala, N., Carpenter, E., Maude, S. L., et al. (2019). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 37(7_suppl), TPS347-TPS.

    Article  Google Scholar 

  274. Tran, B., Horvath, L., Dorff, T. B., Greil, R., Machiels, J.-P. H., Roncolato, F., et al. (2020). Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 38(6_suppl), TPS261-TPS.

    Article  Google Scholar 

  275. Yu, E. Y., Massard, C., Retz, M., Tafreshi, A., Carles Galceran, J., Hammerer, P., et al. (2019). Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 37(7_suppl), 145.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Authors Deepak Ravindranathan, Omar Alhalabi, and Hind Rafei have contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

    Deepak Ravindranathan & Mehmet Asim Bilen

  2. Winship Cancer Institute of Emory University, Atlanta, GA, USA

    Deepak Ravindranathan & Mehmet Asim Bilen

  3. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Omar Alhalabi & Amishi Yogesh Shah

  4. Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Hind Rafei

Authors
  1. Deepak Ravindranathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omar Alhalabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hind Rafei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amishi Yogesh Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehmet Asim Bilen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Amishi Yogesh Shah or Mehmet Asim Bilen .

Editor information

Editors and Affiliations

  1. Professor, Dept. of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Aung Naing

  2. Assistant Professor, Service Chief of Adult Allergy & Immunology, Division of Immunology, Allergy & Retrovirology Baylor College of Medicine and Texas Children’ Hospital, Houston, TX, USA

    Joud Hajjar

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ravindranathan, D., Alhalabi, O., Rafei, H., Shah, A.Y., Bilen, M.A. (2021). Landscape of Immunotherapy in Genitourinary Malignancies. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1342. Springer, Cham. https://doi.org/10.1007/978-3-030-79308-1_5

Download citation

Publish with us

Policies and ethics

Search

Navigation